19:15Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
08:27Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits
Benefits of Self-Esteem
Future Value
03:05Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
The Costs and Benefits of Natural Pedagogy
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 20, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
1Sanofi, Bridgewater, 55 Corporate Drive, Bridgewater, NJ 08807, USA.
The evaluation of medicinal product benefit-risk (BR) profiles has evolved from subjective methods to structured, objective processes over the past 20 years. This shift enhances regulatory decision-making and patient safety.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: